Pilot 4:
Parkinson’s Disease Organoids
“Using midbrain organoids generated from patients with Parkinson’s Disease, we are examining drug responses in a model that closely mirrors human pathology. This showcases how organoids can serve as predictive NAM for clinical drug trials in neurodegenerative research. ”
University of Luxembourg, Research group Developmental & Cellular Biology
About the pilot
- Uses organoids from familial (GBA mutated) PD patients and matched control cell lines which recapitulate key PD hallmarks, including dopaminergic neuron loss
- Assesses drug effects via high-content imaging and PD cellular phenotype analysis
- Compares predictive value against pre-clinical animal model outcomes
- Offers a cost-effective, patient-specific animal-free testing platform for neurodegenerative drug R&D
Participation
- Put your compounds to the test Evaluate PD drug candidates in patientderived organoid models.
- De-risk clinical pipelines Identify failures earlier and save time, cost, and resources before late-stage trials.
- Gain independent proof points Use validation data to strengthen stakeholder confidence
Target Group: Enterprises and SMEs with drug compounds for neurodegenerative diseases (mainly PD), tested in pre-clinical and clinical settings or untested compounds in early clinical development.
Objective
Showcase predictive potential of human brain organoids in preclinical drug evaluation
About the pilot lead
Based at the University of Luxembourg, the Developmental & Cellular Biology group develops advanced human brain models to study both healthy and disease states in the context of neurodegenerative diseases. Using brain organoid and assembloid technologies, the group models physiological and pathological processes, with a strong focus on PD as a growing societal challenge.
For more information, click here: Developmental & Cellular Biology I University of Luxembourg
If you have any quastions, don't hesitate to contact us